- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital Care Center - North Haven6 Devine Street, Fl 1North Haven, CT 06473
Michael Cecchini, MD
Biography
Michael Cecchini, MD, is a medical oncologist who specializes in gastrointestinal cancers, including (but not limited to) colorectal, bile duct, pancreas, esophageal, and stomach cancers. He often cares for patients with advanced gastrointestinal cancers and is an investigator in multiple research trials to help them get treatments that are not always available elsewhere.
“Taking care of patients and spending the time to get to know them is the best part of my job,” Dr. Cecchini says. It helps to draw upon the diverse expertise of colleagues at Smilow and those in non-cancer specialties, he adds. “At Yale we have an excellent multidisciplinary team that will work hard to treat your cancer, manage your symptoms, and deliver the care you deserve as a patient.”
Dr. Cecchini was inspired to become a cancer specialist partly because he wanted to have opportunities to perform research to improve options for his patients. “Few specialties are so integrated with close patient relationships and translational research that can dramatically improve the lives of our patients and minimize side effects,” he says. His translational research includes clinical and lab projects to study DNA damage and the immune response, primarily for colorectal cancer. He is the recipient of a Young Investigator Award from the Conquer Cancer Foundation for research focused on metastatic gastric cancer and 2020 Scholar on the Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program.
Titles
- Assistant Professor of Medicine (Medical Oncology)
- Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers
Education & Training
- Hematology / Oncology FellowYale New Haven Hospital (2018)
- Internal Medicine ResidentYale New Haven Hospital (2015)
- MDAlbert Einstein College of Medicine (2012)
- BSUniversity of California, Santa Cruz, Cell, Molecular, and Developmental Biology (2008)
Additional Information
- The Hematology & Oncology Fellowship Program Annual Research Award: (2021)
- Jean L. Cook MD Memorial Award for Medical Excellence: Albert Einstein College of Medicine (2012)
- Albert Einstein College of Medicine Dean's Award: Albert Einstein College of Medicine (2012)
- National Cancer Institute (2023): Reviewer for NCI study section for R21 and R03.
- SWOG Early Career Investigator, NCI Colon Task Force of the GI Steering Committee (2023 - Present): Member
- ASCO Scientific Review Committee for Colorectal Cancer (2022 - Present): Member
- Yale Cancer Answers (2021 - Present): Presenter/Speaker
- Smilow Shares for Colorectal Cancer (2021 - Present): Presenter/Speaker
- Ambulatory Working Group: Staff and Staffing Subgroup (2020): Member
- Protocol Review Committee (2019 - 2022): Member
- Inpatient Care Committee for Smilow Cancer Hospital (2019 - 2020): Member
- Bridgeport Hospital (2019 - Present): Advances in Gastroesophageal Cancers
- Clinical Cancer Research (2018 - Present): Reviewer
- Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.
- Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.
- Cecchini M, Walther Z, Wei W, Hafez N, Pilat M, Boerner S, Durecki D, Eder J, Schalper K, Chen A, LoRusso P. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors Cancer Research Communications 2023, 3: 1113-1117. PMCID: PMC10292219, DOI: 10.1158/2767-9764.crc-22-0485.
- Clifton G, Rothenberg M, Ascierto P, Begley G, Cecchini M, Eder J, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai S, Provenzano P, Puré E, Ribas A, Schalper K, Fridman W. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop Journal For ImmunoTherapy Of Cancer 2023, 11: e006773. PMID: 37290925, PMCID: PMC10254706, DOI: 10.1136/jitc-2023-006773.
- Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.
- Harding J, Hofheinz R, Elez E, Kuboki Y, Rasco D, Cecchini M, Shen L, He M, Archuadze S, Chhaya N, Pant S. A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers. Journal Of Clinical Oncology 2023, 41: 115-115. DOI: 10.1200/jco.2023.41.4_suppl.115.
- Schwartzberg L, Broder M, Ailawadhi S, Beltran H, Blakely L, Budd G, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk B, Wong D, Campos C, Yermilov I. Impact of early detection on cancer curability: A modified Delphi panel study PLOS ONE 2022, 17: e0279227. PMID: 36542647, PMCID: PMC9770338, DOI: 10.1371/journal.pone.0279227.
- Mokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.
- Harding J, Hofheinz R, Fernandez M, Kuboki Y, Rasco D, Cecchini M, Shen L, Archuadze S, Geng J, Haderk F, Pant S. 371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers Annals Of Oncology 2022, 33: s706. DOI: 10.1016/j.annonc.2022.07.509.
- Li C, Ferro A, Mhatre SK, Lu D, Lawrance M, Li X, Li S, Allen S, Desai J, Fakih M, Cecchini M, Pedersen KS, Kim TY, Reyes-Rivera I, Segal NH, Lenain C. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer Communications Medicine 2022, 2: 90. PMID: 35856081, PMCID: PMC9287310, DOI: 10.1038/s43856-022-00155-y.
- Cecchini M, Chao J, Shyr Y, Cleary J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Hsu C, Stein S, Thumar J, Kortmansky J, Kunstman J, LoRusso P, Ivy P, Lacy J. Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ) Cancer Research 2022, 82: ct170-ct170. DOI: 10.1158/1538-7445.am2022-ct170.
- Cecchini M, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Eder J, Zhang J, Ross J. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. Journal Of Clinical Oncology 2022, 40: 3535-3535. DOI: 10.1200/jco.2022.40.16_suppl.3535.
- Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, , Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study JMIR Cancer 2022, 8: e33859. PMID: 35588361, PMCID: PMC9164098, DOI: 10.2196/33859.
- Beech C, Walther Z, Cecchini M, Gibson J. Tu1119: CLINICOPATHOLOGIC FEATURES AND MOLECULAR LANDSCAPE OF BRAF MUTATED MICROSATELLITE STABLE COLORECTAL CARCINOMA Gastroenterology 2022, 162: s-889-s-890. DOI: 10.1016/s0016-5085(22)62107-3.
- Giner-Calabuig M, De Leon S, Wang J, Fehlmann TD, Ukaegbu C, Gibson J, Alustiza-Fernandez M, Pico MD, Alenda C, Herraiz M, Carrillo-Palau M, Salces I, Reyes J, Ortega SP, Obrador-Hevia A, Cecchini M, Syngal S, Stoffel E, Ellis NA, Sweasy J, Jover R, Llor X, Xicola RM. Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential British Journal Of Cancer 2022, 126: 1595-1603. PMID: 35197584, PMCID: PMC9130322, DOI: 10.1038/s41416-022-01754-1.
- Harding J, Hofheinz R, Elez E, Kuboki Y, Rasco D, Cecchini M, Shen L, Dowling E, Archuadze S, de Pereira B, Pant S. A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Journal Of Clinical Oncology 2022, 40: tps222-tps222. DOI: 10.1200/jco.2022.40.4_suppl.tps222.
- Gabrail N, Tolcher A, Alese O, Cecchini M, Manish P, Park H, Berlin J, Hamilton E, Huang Y, Lu L, Wang J, Shi M, Tong M. A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2022, 40: tps375-tps375. DOI: 10.1200/jco.2022.40.4_suppl.tps375.
- Zhang J, Cecchini M, Desai S, Schalper K. Clinical significance and biomarker potential of MGMT protein measurement in colorectal cancer. Journal Of Clinical Oncology 2022, 40: 136-136. DOI: 10.1200/jco.2022.40.4_suppl.136.
- Patel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, DOI: 10.21037/jgo-21-202.
- Peters GW, Wang S, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky JS, Stein S, Kunz PL, Lattanzi S, Park HSM, Boffa D, Johung KL, Jethwa KR. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: e68. PMID: 34701946, DOI: 10.1016/j.ijrobp.2021.07.422.
- Peters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
- Guo Y, Czeyda-Pommersheim F, Miccio JA, Mahalingam S, Cecchini M, Pahade J. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdominal Radiology 2021, 46: 5609-5617. PMID: 34557934, DOI: 10.1007/s00261-021-03284-5.
- Patel M, Naing A, Burris H, Lin C, Curigliano G, Thistlethwaite F, Minchom A, Ascierto P, De Braud F, Cecchini M, Hanekom W, Sainson R, Wilson R, Quaratino S. A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies. Journal Of Clinical Oncology 2021, 39: 2624-2624. DOI: 10.1200/jco.2021.39.15_suppl.2624.
- Broder M, Ailawadhi S, Beltran H, Blakely L, Budd G, Carr L, Cecchini M, Cobb P, Gibbs S, Kansal A, Kim A, Monk B, Schwartzberg L, Wong D, Yermilov I. Estimates of stage-specific preclinical sojourn time across 21 cancer types. Journal Of Clinical Oncology 2021, 39: e18584-e18584. DOI: 10.1200/jco.2021.39.15_suppl.e18584.
- Desai J, Fakih M, Pedersen K, Hong Y, Segal N, Allen S, Bailey L, Lenain C, Lu D, Sayyed P, Schulze J, Cecchini M. Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer. Journal Of Clinical Oncology 2021, 39: 82-82. DOI: 10.1200/jco.2021.39.3_suppl.82.
- Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients.Uhlig J, Stein S, Lacy J, Cecchini M, Kim K. Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients. Journal Of Clinical Oncology 2021, 39: 462-462. DOI: 10.1200/jco.2021.39.3_suppl.462.
- Miccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.
- Miccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.
- Uhlig J, Stein S, Cecchini M, Kim H. P-320 Genetic testing for microsatellite instability and KRAS mutation in stage IV colorectal cancer: Trends and outcomes from the National Cancer Database Annals Of Oncology 2020, 31: s193-s194. DOI: 10.1016/j.annonc.2020.04.402.
- Goyal L, Lamarca A, Strickler J, Cecchini M, Ahn D, Baiev I, Boileve A, Tazdait M, Hannan L, Jia J, Marble H, Barzi A, Sahai V, Lennerz J, Kelley R, Bekaii-Saab T, Javle M, Uboha N, Harris W, Hollebecque A. The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). Journal Of Clinical Oncology 2020, 38: e16686-e16686. DOI: 10.1200/jco.2020.38.15_suppl.e16686.
- Patel T, Miccio J, Srikumar T, Prsic E, Adelson K, Kozhevnikov D, Patel K, Lacy J, Cecchini M. Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study. Journal Of Clinical Oncology 2020, 38: 770-770. DOI: 10.1200/jco.2020.38.4_suppl.770.
- Patel T, Srikumar T, Miccio J, Lacy J, Stein S, Kortmansky J, Staugaard C, Gambaccini M, Axtmayer A, Cecchini M. Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System. Journal Of Clinical Oncology 2020, 38: 769-769. DOI: 10.1200/jco.2020.38.4_suppl.769.
- Overdijk M, Cecchini M, Strumane K, Brandhorst M, Lingnau A, Parren P, Ellekilde-Pedersen M, Forssmann U, Ahmadi T, Sasser A, Schuurman J, Breij E, LoRusso P. Abstract C025: HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor models Molecular Cancer Therapeutics 2019, 18: c025-c025. DOI: 10.1158/1535-7163.targ-19-c025.
- Miccio J, Cecchini M, Pahade J, Lacy J, Salem R, Johnson S, Blakaj A, Stein S, Kortmansky J, Johung K. OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative Radiation International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e10-e11. DOI: 10.1016/s0360-3016(19)30424-9.
- Cecchini M, Kortmansky J, Lacy J, Fischbach N, Thumar J, Sabbath K, Gomez C, Sporn J, Stein S, Hochster H. A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2019, 37: 630-630. DOI: 10.1200/jco.2019.37.4_suppl.630.
- Cecchini M, Miccio J, Pahade J, Lacy J, Salem R, Johnson S, Stein S, Kortmansky J, Johung K. Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT. Journal Of Clinical Oncology 2019, 37: 437-437. DOI: 10.1200/jco.2019.37.4_suppl.437.
- Cecchini M, LoRusso P, Shyr Y, Ivy S, Sklar J, Dooley K, Lacy J. NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal Of Clinical Oncology 2018, 36: tps4137-tps4137. DOI: 10.1200/jco.2018.36.15_suppl.tps4137.
- Foster Y, Cecchini M, Slater D, Neumeister V, Walther Z, Husain Z, Judson B, Deshpande H. Response to nivolumab in radiation induced, BRCA-2 N372H variant, programed death ligand-1 negative, pleomorphic undifferentiated sarcoma. Journal Of Clinical Oncology 2017, 35: 61-61. DOI: 10.1200/jco.2017.35.7_suppl.61.
- Cecchini M, Salem R, Zaheer Kidwai W, Kortmansky J, Fischbach N, Patel A, Hochster H, Lacy J. Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC). Journal Of Clinical Oncology 2017, 35: 393-393. DOI: 10.1200/jco.2017.35.4_suppl.393.
- Kotani D, Pashtoon K, Cecchini M, Shitara K, Ohtsu A, Ramanathan R, Hochster H, Grothey A, Yoshino T. PD-010 Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer Annals Of Oncology 2016, 27: ii105. PMCID: PMC4984158, DOI: 10.1093/annonc/mdw200.10.
- Deshpande H, Hurwitz M, Cecchini M, Ciarleglio M, Deng Y, Li F, Sherwood M, Petrylak D. A retrospective analysis to assess the validity of multidisciplinary tumor boards using a new tool: The Subspecialty Academic Multidisciplinary Tumor Board score (SAMTB). Journal Of Clinical Oncology 2016, 34: e18188-e18188. DOI: 10.1200/jco.2016.34.15_suppl.e18188.
- Kasi P, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan R, Hochster H, Grothey A, Yoshino T. Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort study. Journal Of Clinical Oncology 2016, 34: e15124-e15124. DOI: 10.1200/jco.2016.34.15_suppl.e15124.
- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital Care Center - North Haven6 Devine Street, Fl 1North Haven, CT 06473
Biography
Michael Cecchini, MD, is a medical oncologist who specializes in gastrointestinal cancers, including (but not limited to) colorectal, bile duct, pancreas, esophageal, and stomach cancers. He often cares for patients with advanced gastrointestinal cancers and is an investigator in multiple research trials to help them get treatments that are not always available elsewhere.
“Taking care of patients and spending the time to get to know them is the best part of my job,” Dr. Cecchini says. It helps to draw upon the diverse expertise of colleagues at Smilow and those in non-cancer specialties, he adds. “At Yale we have an excellent multidisciplinary team that will work hard to treat your cancer, manage your symptoms, and deliver the care you deserve as a patient.”
Dr. Cecchini was inspired to become a cancer specialist partly because he wanted to have opportunities to perform research to improve options for his patients. “Few specialties are so integrated with close patient relationships and translational research that can dramatically improve the lives of our patients and minimize side effects,” he says. His translational research includes clinical and lab projects to study DNA damage and the immune response, primarily for colorectal cancer. He is the recipient of a Young Investigator Award from the Conquer Cancer Foundation for research focused on metastatic gastric cancer and 2020 Scholar on the Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program.
Titles
- Assistant Professor of Medicine (Medical Oncology)
- Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers
Education & Training
- Hematology / Oncology FellowYale New Haven Hospital (2018)
- Internal Medicine ResidentYale New Haven Hospital (2015)
- MDAlbert Einstein College of Medicine (2012)
- BSUniversity of California, Santa Cruz, Cell, Molecular, and Developmental Biology (2008)
Additional Information
- The Hematology & Oncology Fellowship Program Annual Research Award: (2021)
- Jean L. Cook MD Memorial Award for Medical Excellence: Albert Einstein College of Medicine (2012)
- Albert Einstein College of Medicine Dean's Award: Albert Einstein College of Medicine (2012)
- National Cancer Institute (2023): Reviewer for NCI study section for R21 and R03.
- SWOG Early Career Investigator, NCI Colon Task Force of the GI Steering Committee (2023 - Present): Member
- ASCO Scientific Review Committee for Colorectal Cancer (2022 - Present): Member
- Yale Cancer Answers (2021 - Present): Presenter/Speaker
- Smilow Shares for Colorectal Cancer (2021 - Present): Presenter/Speaker
- Ambulatory Working Group: Staff and Staffing Subgroup (2020): Member
- Protocol Review Committee (2019 - 2022): Member
- Inpatient Care Committee for Smilow Cancer Hospital (2019 - 2020): Member
- Bridgeport Hospital (2019 - Present): Advances in Gastroesophageal Cancers
- Clinical Cancer Research (2018 - Present): Reviewer
- Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.
- Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.
- Cecchini M, Walther Z, Wei W, Hafez N, Pilat M, Boerner S, Durecki D, Eder J, Schalper K, Chen A, LoRusso P. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors Cancer Research Communications 2023, 3: 1113-1117. PMCID: PMC10292219, DOI: 10.1158/2767-9764.crc-22-0485.
- Clifton G, Rothenberg M, Ascierto P, Begley G, Cecchini M, Eder J, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai S, Provenzano P, Puré E, Ribas A, Schalper K, Fridman W. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop Journal For ImmunoTherapy Of Cancer 2023, 11: e006773. PMID: 37290925, PMCID: PMC10254706, DOI: 10.1136/jitc-2023-006773.
- Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.
- Harding J, Hofheinz R, Elez E, Kuboki Y, Rasco D, Cecchini M, Shen L, He M, Archuadze S, Chhaya N, Pant S. A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers. Journal Of Clinical Oncology 2023, 41: 115-115. DOI: 10.1200/jco.2023.41.4_suppl.115.
- Schwartzberg L, Broder M, Ailawadhi S, Beltran H, Blakely L, Budd G, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk B, Wong D, Campos C, Yermilov I. Impact of early detection on cancer curability: A modified Delphi panel study PLOS ONE 2022, 17: e0279227. PMID: 36542647, PMCID: PMC9770338, DOI: 10.1371/journal.pone.0279227.
- Mokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.
- Harding J, Hofheinz R, Fernandez M, Kuboki Y, Rasco D, Cecchini M, Shen L, Archuadze S, Geng J, Haderk F, Pant S. 371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers Annals Of Oncology 2022, 33: s706. DOI: 10.1016/j.annonc.2022.07.509.
- Li C, Ferro A, Mhatre SK, Lu D, Lawrance M, Li X, Li S, Allen S, Desai J, Fakih M, Cecchini M, Pedersen KS, Kim TY, Reyes-Rivera I, Segal NH, Lenain C. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer Communications Medicine 2022, 2: 90. PMID: 35856081, PMCID: PMC9287310, DOI: 10.1038/s43856-022-00155-y.
- Cecchini M, Chao J, Shyr Y, Cleary J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Hsu C, Stein S, Thumar J, Kortmansky J, Kunstman J, LoRusso P, Ivy P, Lacy J. Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ) Cancer Research 2022, 82: ct170-ct170. DOI: 10.1158/1538-7445.am2022-ct170.
- Cecchini M, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Eder J, Zhang J, Ross J. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. Journal Of Clinical Oncology 2022, 40: 3535-3535. DOI: 10.1200/jco.2022.40.16_suppl.3535.
- Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, , Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study JMIR Cancer 2022, 8: e33859. PMID: 35588361, PMCID: PMC9164098, DOI: 10.2196/33859.
- Beech C, Walther Z, Cecchini M, Gibson J. Tu1119: CLINICOPATHOLOGIC FEATURES AND MOLECULAR LANDSCAPE OF BRAF MUTATED MICROSATELLITE STABLE COLORECTAL CARCINOMA Gastroenterology 2022, 162: s-889-s-890. DOI: 10.1016/s0016-5085(22)62107-3.
- Giner-Calabuig M, De Leon S, Wang J, Fehlmann TD, Ukaegbu C, Gibson J, Alustiza-Fernandez M, Pico MD, Alenda C, Herraiz M, Carrillo-Palau M, Salces I, Reyes J, Ortega SP, Obrador-Hevia A, Cecchini M, Syngal S, Stoffel E, Ellis NA, Sweasy J, Jover R, Llor X, Xicola RM. Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential British Journal Of Cancer 2022, 126: 1595-1603. PMID: 35197584, PMCID: PMC9130322, DOI: 10.1038/s41416-022-01754-1.
- Harding J, Hofheinz R, Elez E, Kuboki Y, Rasco D, Cecchini M, Shen L, Dowling E, Archuadze S, de Pereira B, Pant S. A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Journal Of Clinical Oncology 2022, 40: tps222-tps222. DOI: 10.1200/jco.2022.40.4_suppl.tps222.
- Gabrail N, Tolcher A, Alese O, Cecchini M, Manish P, Park H, Berlin J, Hamilton E, Huang Y, Lu L, Wang J, Shi M, Tong M. A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2022, 40: tps375-tps375. DOI: 10.1200/jco.2022.40.4_suppl.tps375.
- Zhang J, Cecchini M, Desai S, Schalper K. Clinical significance and biomarker potential of MGMT protein measurement in colorectal cancer. Journal Of Clinical Oncology 2022, 40: 136-136. DOI: 10.1200/jco.2022.40.4_suppl.136.
- Patel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, DOI: 10.21037/jgo-21-202.
- Peters GW, Wang S, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky JS, Stein S, Kunz PL, Lattanzi S, Park HSM, Boffa D, Johung KL, Jethwa KR. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: e68. PMID: 34701946, DOI: 10.1016/j.ijrobp.2021.07.422.
- Peters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
- Guo Y, Czeyda-Pommersheim F, Miccio JA, Mahalingam S, Cecchini M, Pahade J. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdominal Radiology 2021, 46: 5609-5617. PMID: 34557934, DOI: 10.1007/s00261-021-03284-5.
- Patel M, Naing A, Burris H, Lin C, Curigliano G, Thistlethwaite F, Minchom A, Ascierto P, De Braud F, Cecchini M, Hanekom W, Sainson R, Wilson R, Quaratino S. A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies. Journal Of Clinical Oncology 2021, 39: 2624-2624. DOI: 10.1200/jco.2021.39.15_suppl.2624.
- Broder M, Ailawadhi S, Beltran H, Blakely L, Budd G, Carr L, Cecchini M, Cobb P, Gibbs S, Kansal A, Kim A, Monk B, Schwartzberg L, Wong D, Yermilov I. Estimates of stage-specific preclinical sojourn time across 21 cancer types. Journal Of Clinical Oncology 2021, 39: e18584-e18584. DOI: 10.1200/jco.2021.39.15_suppl.e18584.
- Desai J, Fakih M, Pedersen K, Hong Y, Segal N, Allen S, Bailey L, Lenain C, Lu D, Sayyed P, Schulze J, Cecchini M. Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer. Journal Of Clinical Oncology 2021, 39: 82-82. DOI: 10.1200/jco.2021.39.3_suppl.82.
- Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients.Uhlig J, Stein S, Lacy J, Cecchini M, Kim K. Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients. Journal Of Clinical Oncology 2021, 39: 462-462. DOI: 10.1200/jco.2021.39.3_suppl.462.
- Miccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.
- Miccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.
- Uhlig J, Stein S, Cecchini M, Kim H. P-320 Genetic testing for microsatellite instability and KRAS mutation in stage IV colorectal cancer: Trends and outcomes from the National Cancer Database Annals Of Oncology 2020, 31: s193-s194. DOI: 10.1016/j.annonc.2020.04.402.
- Goyal L, Lamarca A, Strickler J, Cecchini M, Ahn D, Baiev I, Boileve A, Tazdait M, Hannan L, Jia J, Marble H, Barzi A, Sahai V, Lennerz J, Kelley R, Bekaii-Saab T, Javle M, Uboha N, Harris W, Hollebecque A. The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). Journal Of Clinical Oncology 2020, 38: e16686-e16686. DOI: 10.1200/jco.2020.38.15_suppl.e16686.
- Patel T, Miccio J, Srikumar T, Prsic E, Adelson K, Kozhevnikov D, Patel K, Lacy J, Cecchini M. Timing and location of palliative care consultation in metastatic pancreatic cancer: A retrospective, single-center observational study. Journal Of Clinical Oncology 2020, 38: 770-770. DOI: 10.1200/jco.2020.38.4_suppl.770.
- Patel T, Srikumar T, Miccio J, Lacy J, Stein S, Kortmansky J, Staugaard C, Gambaccini M, Axtmayer A, Cecchini M. Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System. Journal Of Clinical Oncology 2020, 38: 769-769. DOI: 10.1200/jco.2020.38.4_suppl.769.
- Overdijk M, Cecchini M, Strumane K, Brandhorst M, Lingnau A, Parren P, Ellekilde-Pedersen M, Forssmann U, Ahmadi T, Sasser A, Schuurman J, Breij E, LoRusso P. Abstract C025: HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor models Molecular Cancer Therapeutics 2019, 18: c025-c025. DOI: 10.1158/1535-7163.targ-19-c025.
- Miccio J, Cecchini M, Pahade J, Lacy J, Salem R, Johnson S, Blakaj A, Stein S, Kortmansky J, Johung K. OA23 Outcomes for Patients with Borderline and Locally Advanced Pancreatic Cancer: Induction Chemotherapy ± Radiation Followed by Surgery Compared to Induction Chemotherapy and Consolidative Radiation International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e10-e11. DOI: 10.1016/s0360-3016(19)30424-9.
- Cecchini M, Kortmansky J, Lacy J, Fischbach N, Thumar J, Sabbath K, Gomez C, Sporn J, Stein S, Hochster H. A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2019, 37: 630-630. DOI: 10.1200/jco.2019.37.4_suppl.630.
- Cecchini M, Miccio J, Pahade J, Lacy J, Salem R, Johnson S, Stein S, Kortmansky J, Johung K. Outcomes for patients with borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PC) treated with induction FOLFIRINOX (FFX) +/- radiation (RT) followed by surgery compared to induction FFX followed by consolidative RT. Journal Of Clinical Oncology 2019, 37: 437-437. DOI: 10.1200/jco.2019.37.4_suppl.437.
- Cecchini M, LoRusso P, Shyr Y, Ivy S, Sklar J, Dooley K, Lacy J. NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal Of Clinical Oncology 2018, 36: tps4137-tps4137. DOI: 10.1200/jco.2018.36.15_suppl.tps4137.
- Foster Y, Cecchini M, Slater D, Neumeister V, Walther Z, Husain Z, Judson B, Deshpande H. Response to nivolumab in radiation induced, BRCA-2 N372H variant, programed death ligand-1 negative, pleomorphic undifferentiated sarcoma. Journal Of Clinical Oncology 2017, 35: 61-61. DOI: 10.1200/jco.2017.35.7_suppl.61.
- Cecchini M, Salem R, Zaheer Kidwai W, Kortmansky J, Fischbach N, Patel A, Hochster H, Lacy J. Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC). Journal Of Clinical Oncology 2017, 35: 393-393. DOI: 10.1200/jco.2017.35.4_suppl.393.
- Kotani D, Pashtoon K, Cecchini M, Shitara K, Ohtsu A, Ramanathan R, Hochster H, Grothey A, Yoshino T. PD-010 Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer Annals Of Oncology 2016, 27: ii105. PMCID: PMC4984158, DOI: 10.1093/annonc/mdw200.10.
- Deshpande H, Hurwitz M, Cecchini M, Ciarleglio M, Deng Y, Li F, Sherwood M, Petrylak D. A retrospective analysis to assess the validity of multidisciplinary tumor boards using a new tool: The Subspecialty Academic Multidisciplinary Tumor Board score (SAMTB). Journal Of Clinical Oncology 2016, 34: e18188-e18188. DOI: 10.1200/jco.2016.34.15_suppl.e18188.
- Kasi P, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan R, Hochster H, Grothey A, Yoshino T. Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort study. Journal Of Clinical Oncology 2016, 34: e15124-e15124. DOI: 10.1200/jco.2016.34.15_suppl.e15124.
- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital Care Center - North Haven6 Devine Street, Fl 1North Haven, CT 06473
- Smilow Cancer Hospital Gastrointestinal Cancers ProgramSmilow Cancer Hospital Care Center - North Haven6 Devine Street, Fl 1North Haven, CT 06473